Anticancer-PAM · Anticancer activity of plasma activated medium and its underlying mechanisms: Combined experimental and computational study
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2017-09-01 → 2019-08-31
- EU contribution
- €160,800
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Anticancer activity of plasma activated medium and its underlying mechanisms: Combined experimental and computational study
Cold atmospheric plasma (CAP) is attracting a lot of attention due to its vast biomedical potential. Specifically, the emerging field of the role of CAP in cancer treatment is of high importance. CAP generates a variety of molecular, ionic and radical reactive oxygen and nitrogen species (RONS) upon interaction with ambient gas and aqueous environment of biological substrates. In-vitro studies have shown that CAP has a promising anticancer activity against more than 20 cancer types. However, CAP treatment has certain limitations in the treatment of internal organs of the body. For these circumstances, CAP-irradiated solutions or plasma treated media (PTM) might be a promising alternative. However, the anticancer potential of CAP or PTM (also referred as PAM in our project title) is only scarcely explored, mainly because the underlying mechanisms are still largely unknown. By elucidating and explaining the effects of CAP on various proteins, we can open a long-term perspective for a new class of patient-tailored personalised cancer treatment, contributing to a healthier society.
Data: CORDIS, © European Union
Project objective
Cold atmospheric plasma (CAP) is gaining increasing interest for cancer treatment, although the application is still in its early stages. Besides direct CAP treatment of cancer cells, plasma can also be used to activate a liquid medium, which seems to have similar anti-cancer effects as the plasma itself. This so-called plasma activated medium (PAM) is very promising for cancer treatment, as it can be more generally used, e.g., it might be directly injected into tissue of patients. However, the anticancer potential of PAM is not yet fully understood. This is exactly the focus of this project. We will measure the reactive oxygen and nitrogen species (RONS) concentrations in PAM, and also calculate them with a model for plasma-liquid interaction. In addition, we will study the effect of PAM on a catalase model protein by experiments, and perform atomic scale simulations for the interaction of RONS with this protein, to better understand the effect of PAM on cancer cells, because catalase aids cancer cells in overcoming oxidative stress created by PAM.
Original text from CORDIS.
Participants
- UNIVERSITEIT ANTWERPEN · AntwerpenCoordinatorBelgium
Links
Data: CORDIS, © European Union